Stroke and coronary heart disease in treated hypertension - A prospective cohort study over three decades

Journal of Internal Medicine

Volumn 257, Issue 6, 2005, Pages 496-502

  Almgren, T ^a   Persson, B ^a   Wilhelmsen, L ^a   Rosengren, A ^a   Andersson, O K ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cholesterol; Hypertension; Myocardial infarction; Smoking; Stroke; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SMOKING; STROKE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CORONARY DISEASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 20144377090     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01497.x     Document Type: Article

References (32)

1. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease. Part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
2. Stokes J, III, Kannel WB, Wolf PA, Dágostino RB, Cupples LA. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study - 30 years of follow-up. Hypertension 1989; 13 (Suppl. 5): 133-5.
3. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ 1998; 317: 167-71.
4. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part 2: short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-39
5. Dahlöf B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
6. Australian National Blood Pressure Study Management Committee. The Australian Therapeutic Trial in mild hypertension. Lancet 1980; i: 1261-7.
7. Amery A, Birkenhäger W, Brixko P et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; i: 1349-54.
8. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J 1986; 7: 279-88.
9. Andersson OK, Berglund G, Hansson L et al. Organization and efficacy of an out-patient hypertension clinic. Acta Med Scand 1978; 203: 391-8.
10. Rose GA, Blackburn H. Classification of the electrocardiogram 'Minnesota code', cardiovascular survey methods. World Health Organ Monogr Ser 1968; 56: 98-154.
11. Ray AA. SAS user's Guide: Basics. Cary, NC: SAS Institute, 1982.
12. SAS/STAT software. The PHREG Procedure. Cary, NC: SAS Institute, 1991 (Technical report).
13. Cox DR. Regression models and life tables (with discusson). J R Stat Soc 1972; 34: 187-220.
14. Altman DG, DeStavola BL. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 1994; 13: 301-41.
15. Grimm RH, Leon AS, Hunninghake DB, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double blind controlled trial. Ann Intern Med 1981; 94: 7-11.
16. Day JL, Metcaalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. BMJ 1982; 1145-8.
17. Leeren P, Foss PO, Helgeland A, Hjerman I, Holme I, Lund-Larsen PG. Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet 1980; ii: 4-6.
18. Samuelsson O, Wilhelmsen L, Andersson OK, Pennert K, Berglund G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the Primary Prevention Trial in Göteborg, Sweden. JAMA 1987; 258: 1768-76.
19. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A. Effect on angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
20. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B. Randomised trial in old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999; 354: 1751-6.
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting-enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
22. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989; 320: 904-10.
23. Rutan GH, Kuller LH, James PH. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Hypertension 1988; 77: 504-14.
24. Nielsen WB, Vestbo J, Jensen GB. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. J Hum Hypertens 1995; 9: 175-80.
25. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255-64.
26. Staessen JA, Fagard R, Thijs L et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.
27. Hansson L, Zanchetti A, Carruthers SG et al. for the HOT Study group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
28. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overview on randomised trials. Lancet 2000; 356: 1955-64.
29. The 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
30. Vokó Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JCM, Breteler MB. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999; 34: 1181-5.
31. MRC Trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97-104.
32. Harmsen P, Rosengren A, Tsipogianni B, Wilhelmsen L. Risk factors for stroke in middle-aged men in Göteborg, Sweden. Stroke 1990; 21: 223-9.